Xiamen Kingdomway Group Valuation

Q: What is the Fair Price of 002626 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002626 (CN¥15.83) is trading above our estimate of [[fair value]] (CN¥1.55)

Is 002626 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002626 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002626 (CN¥15.83) is trading above our estimate of fair value (CN¥1.55)

Significantly Below Fair Value: 002626 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002626?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 002626. This is calculated by dividing 002626's market cap by their current preferred multiple.
What is 002626's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥9.66b

002626 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	21.5x
PEG Ratio	1.2x

Price to Earnings Ratio vs Peers

How does 002626's PE Ratio compare to its peers?

The above table shows the PE ratio for 002626 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	85.6x
600812 North China Pharmaceutical Company.Ltd	192.6x	n/a	CN¥9.7b
688658 Youcare Pharmaceutical Group	94x	41.9%	CN¥9.0b
300026 Tianjin Chase Sun PharmaceuticalLtd	39.6x	23.2%	CN¥12.2b
000650 Renhe PharmacyLtd	16.1x	n/a	CN¥8.8b
002626 Xiamen Kingdomway Group	43.3x	35.5%	CN¥9.7b

Price-To-Earnings vs Peers: 002626 is good value based on its Price-To-Earnings Ratio (43.3x) compared to the peer average (85.6x).

Price to Earnings Ratio vs Industry

How does 002626's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 002626 is expensive based on its Price-To-Earnings Ratio (43.3x) compared to the CN Pharmaceuticals industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 002626's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002626 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	43.3x
Fair PE Ratio	36.1x

Price-To-Earnings vs Fair Ratio: 002626 is expensive based on its Price-To-Earnings Ratio (43.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.